Drug Profile


Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Carbamates; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Raynaud's disease; Systemic scleroderma

Most Recent Events

  • 01 Dec 2016 Bayer completes a phase III trial for Pulmonary Hypertension in the US, Canada, the UK, Belgium, Czech Republic, France, Germany, Italy and Switzerland (NCT02007629)
  • 01 Oct 2016 Bayer completes a phase I trial for pharmacokinetic interaction trial for Pulmonary hypertension (In patients with HIV infections) in USA (NCT02556268)
  • 03 Sep 2016 Efficacy data from the phase III PATENT-1 trial in Pulmonary arterial hypertension presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top